William G. Warren
Alderley Park, Cheshire
Alderley Edge, ENG, United Kingdom
Alderley Edge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.
Journal: British journal of clinical pharmacology
Published: March 30, 2026
Evaluating FABP5 as a Therapeutic Target for Pain Management.
Journal: European journal of pain (London, England)
Published: October 14, 2025
The emerging role of fatty acid-binding protein 3 (FABP3) in cancer.
Journal: Drug discovery today
Published: September 02, 2025
ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models.
Journal: The Journal of investigative dermatology
Published: October 25, 2024
Potential safety implications of fatty acid-binding protein inhibition.
Journal: Toxicology and applied pharmacology
Published: June 07, 2024
ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models.
Journal: European journal of pain (London, England)
Published: May 02, 2024
Endocannabinoid metabolism inhibition has no effect on spontaneous fear recovery or extinction resistance in Lister hooded rats.
Journal: Frontiers in pharmacology
Published: October 28, 2022
Cannabidiol Prevents Spontaneous Fear Recovery after Extinction and Ameliorates Stress-Induced Extinction Resistance.
Journal: International journal of molecular sciences
Published: July 18, 2022
URB597 induces subtle changes to aggression in adult Lister Hooded rats.
Journal: Frontiers in psychiatry
Published: March 10, 2022
In it together? The case for endocannabinoid-noradrenergic interactions in fear extinction.
Journal: The European journal of neuroscience
Published: July 16, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026